Page 60

Translation & Commercialisation

High-Value Specialty Medicine, Biosimilars and Premium Pricing Portfolio Drive Growth in the Global Generic Pharmaceuticals Market Emerging markets are the next big opportunity after the US, says Frost & Sullivan. Increased life expectancy, a growing aged population cohort, and the higher incidence of chronic lifestyle-related diseases are encouraging the use generic pharmaceuticals as governments and healthcare service providers strive to contain costs. Impending patent expiries of key drugs and a promising pipeline of next-gen high value-added biosimilars too will sustain double digit growth for generics. On the flip side, increasing global competition, downward pricing pressure, and tightening regulations will challenge market participants. Further, professionals and patients often prefer branded drugs over generics. Using innovative production platforms to develop lower cost biosimilars as well as a premium priced portfolio can offer greater mileage to generics companies. Recent analysis from Frost & Sullivan, Global Generic Pharmaceuticals Market, finds that generic drugs earned revenues of $330.87 billion in 2015, with a 37% share of the global pharmaceutical market. This is expected to reach $557.37 billion by the end of 2020. In fact, the generics segment is growing at a compound annual growth rate of 11% for this period, while the global pharmaceutical market is growing at a lower CAGR of 9.8%. By 2020, speciality and biosimilars will account for up to 70 % share of generics. “Patent expiration and increased usage of traditional generic drugs are curbing the cost of drugs, compelling the industry to invest in specialty medicines,” said Frost & Sullivan Transformational Health Industry Manager Sanjeev Kumar. “With innovation and technology, generics can be enhanced to deliver additional benefits. Furthermore, to beat the competition, several generics companies in developed countries are transforming themselves from low-margin formulation to high-margin formulation manufacturers.”

The US remains the largest generic pharmaceuticals market, characterised by high profit margins, high levels of generic prescription by doctors, strong intellectual property legislations, retailers’ purchasing price, and pricing levels determined by demand. Europe may emerge as a game changer with the early adoption of biosimilar drugs. “The next big opportunity, however, lies in emerging markets,” noted Kumar. “The availability of cheap labour, inexpensive production methods, skilled personnel, and sound infrastructure make India and China the most sought after destinations for import of generics by developed markets.” While the economic boom and healthcare reforms make China lucrative, India is a major market for consumption as well as manufacturing of generics. The country targets exports of more than 40 % to the US each year. Dominated by branded generics, the Indian market will see higher demand after the implementation of universal health coverage. Web Address: www.frost.com

60 | ghp September 2016

Profile for AI Global Media

GHP September 2016  

GHP September 2016  

Advertisement